MIST.NASDAQMilestone Pharmaceuticals INC

SCHEDULE 13G/A: BlackRock Divests Entire Stake in Milestone Pharmaceuticals, Filing Shows

Sentiment:

Beneficial Ownership Disclosure 22 April 2025 1:32 PM

📋All filings for Milestone Pharmaceuticals INC

BlackRock, Inc. has filed an amended Schedule 13G indicating it no longer holds any beneficial ownership in Milestone Pharmaceuticals Inc., reducing its stake to 0.0%.

Worse than expectedBlackRock, Inc. has reduced its beneficial ownership in Milestone Pharmaceuticals Inc. to 0.0%, indicating a complete divestment of its stake, which is a negative development for the company.

Summary

BlackRock, Inc. filed an Amendment No. 13 to Schedule 13G concerning its beneficial ownership in Milestone Pharmaceuticals Inc.
The filing reports that BlackRock's aggregate beneficial ownership in Milestone Pharmaceuticals Inc. has decreased to 0.0%.
BlackRock now holds 0 shares with sole voting, shared voting, sole dispositive, or shared dispositive power.
The event requiring this filing occurred on March 31, 2025, and the statement was signed on April 22, 2025.
BlackRock certifies that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
A new Power of Attorney document, dated January 21, 2025, was included, revoking a previous one from April 30, 2023.

Sentiment

Score: 3

Explanation: The complete divestment by BlackRock, Inc. of its stake in Milestone Pharmaceuticals Inc. is a negative signal, as it indicates a lack of continued investment interest from a major institutional holder.

Negatives

BlackRock, Inc., a significant institutional investor, has completely divested its beneficial ownership in Milestone Pharmaceuticals Inc., reducing its stake to 0.0%.
This complete divestment by a major institutional holder could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in investment strategy regarding Milestone Pharmaceuticals.

Future Outlook

Industry Context

This filing is a standard regulatory disclosure by a large asset manager, BlackRock, Inc., detailing a change in its passive investment holdings. It reflects a portfolio adjustment rather than a specific industry trend for the pharmaceutical sector, though a major institutional divestment could be interpreted by the market as a signal regarding the specific company.

Stakeholder Impact

Shareholders: Potential negative impact due to a major institutional investor exiting, which could lead to decreased confidence and potential share price pressure.

Key Dates

Date	Description
04/30/2023	Date of previous Power of Attorney document, which was revoked.
01/21/2025	Date of new Power of Attorney document.
03/31/2025	Date of event which required the filing of this statement (BlackRock's ownership change).
04/22/2025	Date the Schedule 13G/A was signed by BlackRock.

Recommendation

sell

Keywords

Milestone Pharmaceuticals Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Institutional Investor, Stock Ownership, SEC Filing, Investment Divestment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.